scholarly journals A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

2020 ◽  
Vol 9 (3) ◽  
pp. 625-639
Author(s):  
Shashikant Sharma ◽  
◽  
Mujtaba Khan ◽  
Alok Chaturvedi
Keyword(s):  
Retrospective Study ◽  
Retinal Vein Occlusion ◽  
Vein Occlusion

scholarly journals Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes

2010 ◽  
Vol 90 (4) ◽  
pp. 357-361 ◽  
Author(s):  
Nathalie Puche ◽  
Agnès Glacet ◽  
Gérard Mimoun ◽  
Alain Zourdani ◽  
Gabriel Coscas ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion

Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study

2022 ◽  
Author(s):  
Francesco Paciullo ◽  
Paola Santina Menduno ◽  
Davide Tucci ◽  
Anna Caricato ◽  
Carlo Cagini ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Clinical Outcome ◽  
Vitamin B12 ◽  
Retinal Vein Occlusion ◽  
Vein Occlusion

Intravitreal dexamethasone for central retinal vein occlusion with low visual acuity: a retrospective study

2013 ◽  
Vol 97 (6) ◽  
pp. 796-797 ◽  
Author(s):  
Christiana Dinah ◽  
Kapka Nenova ◽  
Sreekumari Pushpoth ◽  
Ibraheem El-Ghrably ◽  
Deepali Varma ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Retrospective Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone ◽  
Central Retinal Vein

A retrospective study of the influence of the vitreomacular interface on macular oedema secondary to retinal vein occlusion

2017 ◽  
Vol 101 (10) ◽  
pp. 1340-1345 ◽  
Author(s):  
Rishi P Singh ◽  
Karishma A Habbu ◽  
Rumneek Bedi ◽  
Fabiana Q Silva ◽  
Justis P Ehlers ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Vein Occlusion ◽  
Vitreomacular Interface

scholarly journals The Systemic and Ocular Risk Factors for Retinal Vein Occlusion: A Retrospective Study

2021 ◽  
Author(s):  
Jiacheng Ye ◽  
Min Zhou ◽  
Congyao Wang ◽  
Pengxia Wan
Keyword(s):  
Risk Factors ◽  
Visual Acuity ◽  
Retrospective Study ◽  
Endothelial Dysfunction ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Retinal Thickness ◽  
Low Vision ◽  
Vein Occlusion ◽  
Central Retinal Vein

Abstract BACKGROUND: We sought to evaluate the systemic and ocular risk factors for severity on visual acuity and central retinal thickness in macular edema secondary to retinal vein occlusion (RVO-ME). METHODS: This retrospective study included 46 RVO-ME patients in The First Affiliated Hospital of Sun Yat-sen University from January 2015 to November 2019. Systemic examinations include blood pressure, blood glucose, blood lipids, vascular endothelial function, and carotid artery color ultrasound. Ocular examinations include the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT). The integrity of the outer retina was evaluated as well. According to the baseline BCVA and CRT levels, the patients were divided into high vision group and low vision group, high CRT group, and low CRT group. Multivariate logistic regression analyses were performed to analyze the risk factors on baseline BCVA and CRT.RESULTS: We enrolled 19 eyes of CRVO (central retinal vein occlusion) and 27 eyes of BRVO (branch retinal vein occlusion). We identified 31 (67.4%) as high CRT and 23 (50.0%) as poor VA of 46 patients on admission. There were 15 cases of BRVO in the high CRT group (48.4%) and 12 cases in the low CRT group (80.0%). The type of disease (BRVO/CRVO) was an independent factor of baseline CRT (P=0.017). Endothelial dysfunction correlates with baseline BCVA independently (P=0.038). Ellipsoidal zone (EZ) destruction was found in 19 cases (82.6%) in the low vision group and 6 cases (26.1%) in the high vision group. EZ integrity correlates with baseline BCVA independently (P=0.017). CONCLUSION: The central retinal vein occlusion (CRVO) has markedly higher CRT than branch retinal vein occlusion (BRVO). Endothelial dysfunction and disrupted ellipsoidal zone were significantly associated with poor baseline VA on admission.

Platelet Coagulant Activities and Retinal Vein Thrombosis

1977 ◽  
Vol 38 (02) ◽  
pp. 0399-0406 ◽  
Author(s):  
Peter N. Walsh ◽  
Richard E. Goldberg ◽  
Richard L. Tax ◽  
Larry E. Magargal
Keyword(s):  
Platelet Aggregation ◽  
Venous Thrombosis ◽  
Retinal Vein Occlusion ◽  
Serotonin Release ◽  
Platelet Factor ◽  
Trigger Mechanism ◽  
Local Conditions ◽  
Plasma Coagulation ◽  
Vein Thrombosis ◽  
Vein Occlusion

SummaryTo determine whether platelets play a role in the pathogenesis of retinal vein occlusion (RVO), platelets and coagulation were evaluated in 28 patients with RVO. Platelet coagulant activities concerned with the initiation and early stages of intrinsic coagulation were 2–4 fold increased in 9 patients with acute primary RVO but not in patients with acute secondary (10 patients) or chronic (9 patients) RVO. Platelet factor 3 activity, platelet aggregation, serotonin release by platelets and plasma coagulation were normal in all patients. Platelets may provide a trigger mechanism for venous thrombosis in the eye when local conditions permit.

Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion

1994 ◽  
Vol 72 (01) ◽  
pp. 039-043 ◽  
Author(s):  
Francesco Bandello ◽  
Silvana Vigano’ D’Angelo ◽  
Mariella Parlavecchia ◽  
Alessandra Tavola ◽  
Patrizia Della Valle ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Specific Treatment ◽  
Fibrin Deposition ◽  
Heparin Cofactor Ii ◽  
Lipoprotein A ◽  
Vein Occlusion ◽  
Acute Event ◽  
D Dimer ◽  
Central Retinal Vein

SummaryA series of coagulation parameters and lipoprotein(a) (Lp(a)) were explored in plasma from 40 patients with central retinal vein occlusion (CRVO, non-ischemic type n = 12; ischemic type n = 28) free of local and systemic predisposing factors, 1 to 12 months after the acute event. Forty age- and sex-matched patients with cataract served as controls. Prothrombin fragment 1.2 (FI.2), D-dimer, FVII:C - but not FVII: Ag - were higher and fibrinogen was lower in CRVO patients than in controls. Patients with non-ischemic CRVO had higher FI .2 and FVII:C and lower heparin cofactor II than patients with ischemic CRVO. Lp(a) levels greater than 300 mg/1 were observed in 12 patients with CRVO and in 4 controls (30% vs 10%, p <0.025). Patients with high Lp(a) - consistently associated with the S2 phenotype - had higher FVII:C, FVII:C/Ag ratio, and fibrinogen than the remaining CRVO patients. Plasma FI.2 and D-dimer correlated fairly in controls (r = 0.41) and patients with normal Lp(a) levels (r = 0.55), but they did not in the group of patients with high Lp(a) (r = 0.19), where the latter parameter was negatively related to D-dimer (r = −0.55). There was no dependence of the abnormalities observed on the time elapsed from vein occlusion. The findings of activated FVII and high FI.2, D-dimer, and Lp(a) are not uncommon in patients with CRVO. Increased thrombin formation with fibrin deposition and impaired fibrinolysis may play a role in the pathophysiology of CRVO and require specific treatment

Sign in / Sign up

Export Citation Format

Share Document